Kyowa Kirin Co Ltd
TSE:4151

Watchlist Manager
Kyowa Kirin Co Ltd Logo
Kyowa Kirin Co Ltd
TSE:4151
Watchlist
Price: 2 379.5 JPY -0.27%
Market Cap: 1.3T JPY
Have any thoughts about
Kyowa Kirin Co Ltd?
Write Note

Kyowa Kirin Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kyowa Kirin Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Kyowa Kirin Co Ltd
TSE:4151
Operating Income
ÂĄ100.3B
CAGR 3-Years
24%
CAGR 5-Years
12%
CAGR 10-Years
11%
Takeda Pharmaceutical Co Ltd
TSE:4502
Operating Income
ÂĄ541.9B
CAGR 3-Years
-10%
CAGR 5-Years
18%
CAGR 10-Years
16%
Daiichi Sankyo Co Ltd
TSE:4568
Operating Income
ÂĄ303.4B
CAGR 3-Years
50%
CAGR 5-Years
22%
CAGR 10-Years
10%
Otsuka Holdings Co Ltd
TSE:4578
Operating Income
ÂĄ400.1B
CAGR 3-Years
30%
CAGR 5-Years
26%
CAGR 10-Years
6%
Chugai Pharmaceutical Co Ltd
TSE:4519
Operating Income
ÂĄ540.2B
CAGR 3-Years
15%
CAGR 5-Years
24%
CAGR 10-Years
21%
Astellas Pharma Inc
TSE:4503
Operating Income
ÂĄ120.4B
CAGR 3-Years
-10%
CAGR 5-Years
-16%
CAGR 10-Years
-3%
No Stocks Found

Kyowa Kirin Co Ltd
Glance View

Market Cap
1.2T JPY
Industry
Pharmaceuticals

Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.

Intrinsic Value
3 567.82 JPY
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Kyowa Kirin Co Ltd's Operating Income?
Operating Income
100.3B JPY

Based on the financial report for Sep 30, 2024, Kyowa Kirin Co Ltd's Operating Income amounts to 100.3B JPY.

What is Kyowa Kirin Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
11%

Over the last year, the Operating Income growth was 24%. The average annual Operating Income growth rates for Kyowa Kirin Co Ltd have been 24% over the past three years , 12% over the past five years , and 11% over the past ten years .

Back to Top